Efficacy of Aprepitant (Emend®) in Children
Efficacy of Aprepitant (Emend®) in Children Receiving Highly Emetogenic Chemotherapy
Sponsor: University of Oklahoma
A PHASE3 clinical study on Childhood Cancer and Nausea, this trial is completed. The trial is conducted by University of Oklahoma and has accumulated 10 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE3
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Mar 2019 — Apr 2020 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Recruiting PHASE3
Status: Unknown Status → Recruiting
-
Feb 2017 — Apr 2017 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Oklahoma
For direct contact, visit the study record on ClinicalTrials.gov .